Anticancer activity of Nigella sativa (Black Seed) - A review

American Journal of Chinese Medicine

Volumn 39, Issue 6, 2011, Pages 1075-1091

  Randhawa, Mohammad Akram ^a   Alghamdi, Mastour Safar ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Alpha Hederin; Anticancer; Combination; Derivatives; Mechanism; Nigella sativa; Thymoquinone

Indexed keywords

ALPHA HEDERIN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; NIGELLA SATIVA EXTRACT; OXALIPLATIN; P21 ACTIVATED KINASE; PROTEIN BAX; PROTEIN P27; THYMOQUINONE; TRANSCRIPTION FACTOR E2F1;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLACK CUMIN; BREAST CARCINOMA; CANCER INVASION; CARCINOGENICITY; CELL ACTIVITY; CELL PROLIFERATION; COLON CARCINOMA; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA FRAGMENTATION; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; EHRLICH ASCITES TUMOR; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; METASTASIS; NATURAL KILLER CELL; NECROSIS; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SARCOMA; SKIN CARCINOGENESIS; SPLEEN TUMOR; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; NEOPLASMS; NIGELLA SATIVA; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 81155135198     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X1100941X     Document Type: Review

References (71)

1. Abusnina, A., M. Alhosin, T. Keravis, C.D. Muller, G. Fuhrmann, C. Bronner and C. Lugnier. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell Signal. 23(1): 152-160, 2011.
2. Ahmed, W.A., S.A. Hassan, F.M. Galeb, M.A. El-Taweel and F.A. Abu-Bedair. The in vitro promising therapeutic activity of thymoquinone on hepatocellular carcinoma (HepG2) cell line. Global Veterinaria 2(5): 233-241, 2008.
3. Ait Mbarek, L., H. Ait Mouse, N. Elabbadi, M. Bensalah, A. Gamouh, R.A. Aboufatima, A. Benharref, A. Chait, M. Kamal, A. Dalal and A. Zyad. Anti-tumor properties of black seed (Nigella sativa L.) extract. Braz. J. Med. Biol. Res. 40(6): 839-847, 2007.
4. Al-Ali, A., A. Alkhawajah, M.A. Randhawa and N.A. Shaikh. Oral and intraperitoneal LD50 of thymoquinone, an active peinciple of Nigella sativa, in mice and rats. J. Ayub Med. Coll. 20(2): 25-27, 2008.
5. Al-Bukhari, M.I. In: Sahi Al-Bukhari, The Collection of Authentic Sayings of Prophet Mohammad (peace be upon him), Division 71 on Medicine, 2nd ed. Hilal Yayinlari, Ankara, Turkey, 1976.
6. Al-Jishi, S.A.A. A study of Nigella sativa on blood hemostatic functions. M.Sc. Thesis, King Faisal University, Dammam, Saudi Arabia, 2000.
7. Alhosin, M., A. Abusnina, M. Achour, T. Sharif, C. Muller, J. Peluso, T. Chataigneau, C. Lugnier, V.B. Schini-Kerth, C. Bronner and G. Fuhrmann. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem. Pharmacol. 79(9): 1251-1260, 2010.
8. Ali, B.H. and G. Blunden. Pharmacological and toxicological properties of Nigella sativa. Phytother. Res. 17(4): 299-305, 2003.
9. Awad, E.M. In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by Nigella sativa oil. Phytomedicine 12(1-2): 100-107, 2005.
10. Badary, O.A. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its anti-tumor activity in mice. J. Ethnopharmacol. 67(2): 135-142, 1999.
11. Badary, O.A. and A.M. Gamal El-din. Inhibitory effect of thymoquinone against 20-methyl-chlolanthrene-induced fibrosarcoma tumorigenesis. Cancer Detect. Prev. 25(4): 362-368, 2001.
12. Badary, O.A., O.A. Al-Shabana, M.N. Nagi, A.M. Al-Bekairi and M.M.A. Elmazar. Acute and subchronic toxicity of thymoquinone in mice. Drug Devel. Res. 44: 56-61, 1998.
13. Badary, O.A., O.A. Al-Shabanah, M.N. Nagi, A.C. Al-Rikabi and M.M. Elmazar. Inhibition of benzo (a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur. J. Cancer Prev. 8(5): 435-440, 1999.
14. Banerjee, S., A.O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, F.H. Sarkar and R.M. Mohammad. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 69(13): 5575-5583, 2009.
15. Banerjee, S., S. Padhye, A. Azmi, Z. Wang, P.A. Philip, O. Kucuk, F.H. Sarkar and R.M. Mohammad. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr. Cancer 62(7): 938-946, 2010a.
16. Banerjee, S., A.S. Azmi, S. Padhye, M.W. Singh, J.B. Baruah, P.A. Philip, F.H. Sarkar and R.M. Mohammad. Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm. Res. 27(6): 1146-1158, 2010b.
17. Bawadi, H.A., R.R. Bansode and J.N. Losso. Thymoquinone in the control of hypoxia-induced angiogenic disease biomarkers: insight into the mechanism of action in vitro. In: IFT Annual Meeting, 12 July, Las Vegas NV USA, 2004.
18. Benson, C., S. Kaye, P. Workman, M. Garrett and J. de Bono. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br. J. Cancer 92(1): 7-12, 2005.
19. Bottex-Gauthier, C., S. Pollet, A. Favier and D.R. Vidal. The Rel/NF-kappa-B transcription factors: complex role in cell regulation. Pathol. Biol. 50(3): 204-211, 2002.
20. Breyer, S., K. Effenberger and R. Schobert. Effects of thymoquinone-fatty acid conjugates on cancer cells. Chem. Med. Chem. 4(5): 761-768, 2009.
21. Bun, S.S., R. Elias, B. Baghdikian, J. Ciccolini, E. Ollivier and G. Balansard. Alpha-hederin potentiates 5-FU antitumor activity in human colon adenocarcinoma cells. Phytother. Res. 22(10): 1299-1302, 2008.
22. Cecarinin, V., L. Quassinti, A. Di-Blasio, L. Bonfili, M. Bramucci, G. Lupidi, M. Cuccioloni, M. Mozzicafreddo, M. Angeletti and A.M. Eleuteri. Effects of thymoquinone on isolated proteosomes. FEBS J. 277(9): 2128-2141, 2010.
23. Chahrour, O., L. Xiangrui, L. Franki, A. Abdullah, C. Midgley and W. Shudong. Synthesis, Design, and biological evaluation of thymoquinone derivatives and ON01910 derivatives as anticancer agents. Abstract in National Cancer Research Institute Conference, B.T. Convention Center, U.K., 7-10 November, 2010.
24. Danloy, S., J. Quetin-Leclercq, P. Coucke and M. Gillet. Effects of alpha-hederin, a soponin extracted from Hedera helix, on cell cultured in vitro. Planta Med. 60(1): 45-49, 1994.
25. Effenberger-Neidnicht, K. and R. Schobert. Combinatorial effects of thymoquinone on the anti-cancer activity of doxorubicin. Cancer Chemother. Pharmacol. 67(4): 867-874, 2010.
26. El-Aziz, M.A., H.A. Hassan, M.H. Mohamed, A.R. Meki, S.K. Abdul-Ghaffar and M.R. Hussein. The biochemical and morphological alterations following administration of melatonin, retinoic acid and Nigella sativa in mammary carcinoma: an animal model. Int. J. Exp. Pathol. 86(6): 383-396, 2005.
27. El-Kadi, A. and O. Kandil. Effect of Nigella sativa (the black seed) on immunity. In: Proceedings of the Fourth International Conference on Islamic Medicine, 4 November, Kuwait, 1986, pp. 344-348.
28. El-Mahdy, M.A., Q. Zhu, Q.E. Wang, G. Wani and A.A. Wani. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int. J. Cancer 117: 409-417, 2005.
29. El-Najjar, N., M. Chatila, H. Moukadem, H. Vuorela, M. Ocker, M. Gandesiri, R. Schneider-Stock and H. Gali-Muhtasib. Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 15(2): 183-195, 2010.
30. Farah, I.O. and R.A. Begum. Effect of Nigella sativa (N. sativa L.) and oxidative stress on survival pattern of MCF-7 breast cancer cells. Biomed. Sci. Instrum. 39: 359-364, 2003.
31. Feller, G., S. Kugel, D. Moonshine, V. Chalifa-Caspi, M. Scholz, D. Prüfer, T. Rabinski, K.J. Müller and R. Ofir. African descents are more sensitive than European descents to the antitumor compounds alpha-hederin and kalopanaxsaponin I. Planta Med. 76(16): 1847-1851, 2010.
32. Gali-Muhtasib, H. and N. Bakkar. Modulating cell cycle: current applications and prospects for future drug development. Curr. Cancer Drug Targets 2(4): 309-336, 2002.
33. Gali-Muhtasib, H., A. Roessner and R. Schneider-Stock. Thymoquinone: a promising anti-cancer drug from natural sources. Int. J. Biochem. Cell Biol. 38(8): 1249-1253, 2006.
34. Gali-Muhtasib, H., D. Kuester, C. Mawrin, K. Bajbouj, A. Diestel, M. Acker, C. Habold, C. Foltzer-Jourdainne, P. Schoenfeld, B. Peters, M. Diab-Assaf, W. Itani, H. Lippert, A. Roessner and R. Schneider-Stock. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res. 68(14): 5609-5618, 2008.
35. Gali-Muhtasib, H., M. Diab-Assaf, C. Boltz, J. Al-Hmaira, A. Roessner and R. Schneider-Stock. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer via a p53-dependent mechanism. Int. J. Oncol. 25(4): 857-866, 2004.
36. Gurung, R.L., S.N. Lim, A.K. Khaw, J.F. Soon, K. Shenoy, A.S. Mohamed, M. Jayapal, S. Sethu, R. Baskar and M.P. Hande. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One 5(8): e12124, 2010.
37. Hassan, S.A., W.A. Ahmed, F.M. Galeb, M.A. El-Taweel and F.A. Abu-Bedair. In vitro challenge using thymoquinone on hepatocellular carcinoma (HepG2) cell line. Iran J. Pharm. Res. 7(4): 283-290, 2008.
38. Iddamaldeniya, S.S., M.I. Thabrew, S.M. Wickramsinghe, N. Ratnatunge and M.G. Thammitiya-godage. A long term investigation of the anti-hepatocarcinogenic potencial of an indigenous medicine comprised of Nigella sativa, Hemidesmus indicus and Smilax glabra. J. Carcinog. 5: 11, 2006.
39. Iddamaldeniya, S.S., N. Wickramsinghe, I. Thabrew, N. Ratnatunge and M.G. Thammitiyagodage. Protection against diethylnitrosamine-induced hepatocarcinogenesis by an indigenous medicine comprised of Nigella sativa, Hemidesmus indicus and Smilax glabra: a preliminary study. J. Carcinog. 3(1): 6, 2003.
40. Islam, S.N., P. Begum, T. Ahsan, S. Huque and M. Ahsan. Immunosuppressive and cytotoxic properties of Nigella sativa. Phytother. Res. 18(5): 395-398, 2004.
41. Jafri, S.H., J. Glass, R. Shi, S. Zhang, M. Prince and H. Kleiner-Hancock. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J. Exp. Clin. Cancer Res. 29: 87, 2010.
42. Kaseb, A.O., K. Chinnakannu, D. Chen, A. Sivanandam, S. Tejwani, M. Menon, Q.P. Dou and G.P. Reddy. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 67(16): 7782-7788, 2007.
43. Khan, N. and S. Sultana. Inhibition of two stage renal carcinogenesis, oxidative damage and hyperproliferative response by Nigella sativa. Eur. J. Cancer Prev. 14(2): 159-168, 2005.
44. Koka, P.S., D. Mondal, M. Schultz, A.B. Abdel-Mageed and K.C. Agrawal. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp. Biol. Med. 235(6): 751-760, 2010.
45. Kumara, S.S. and B.T. Huat. Extraction, isolation and characterization of anti-tumor principle, alpha-hedrin, from the seeds of Nigella sativa. Planta Med. 67(1): 29-32, 2001.
46. Mabrouk, G.M., S.S. Moselhy, S.F. Zohny, E.M. Ali, T.E. Helal, A.A. Amin and A.A. Khalifa. Inhibition of methylnitrosourea (MNU) induced oxidative stress and carcinogenesis by orally administered honey and Nigella sativa in Sprague Dawley rats. J. Exp. Clin. Cancer Res. 21(3): 341-346, 2002.
47. Majdalawieh, A.F., R. Hmaidan and R.I. Carr. Nigella sativa modulates splenocyte proliferation, Th1/Th2 cytokine profile, macrophage function and NK anti-tumor activity. J. Ethno-pharmacol. 131(2): 268-275, 2010.
48. Mansour, M.A., O.T. Ginwai, T. El-Hadiya, A.S. El-Khatib, O.A. Al-Shabanah and H.A. Al-Sawaf. Effects of volatile oil constituents of Nigella sativa on carbon tetrachloride-induced hepato-toxicity in mice: evidence for antioxidant effects of thymoquinone. Res. Commun. Mol. Pathol. Pharmacol. 110: 239-251, 2001.
49. Norwood, A.A., M. Tan, M. May, M. Tucci and H. Benghuzzi. Comparison of potential che-motherapeutic agents, 5-fluorouracil, green tea and thymoquinone on colon cancer cells. Biomed. Sci. Instrum. 42: 350-356, 2006.
50. Norwood, A.A., M. Tucci and H. Benghuzzi. A comparison of 5-fluorouracil and natural che-motherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells. Biomed. Sci. Instrum. 43: 272-277, 2007.
51. Padhye, S., S. Banerjee, A. Ahmad, R. Mohammad and F.H. Sarkar. From here to eternity-the secret of pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther. 6: 495-510, 2008.
52. Ramadevi Mani, S. and B.S. Lakshmi. G1 arrest and caspase-mediated apoptosis in HL-60 cells by dichloromethane extract of Centrosema pubescens. Am. J. Chin. Med. 38: 1143-1159, 2010.
53. Randhawa, M.A. and M.S. Alghamdi. A review of the pharmaco-therapeutic effects of Nigella sativa. Pakistan J. Med. Res. 41(2): 77-83, 2002.
54. Ravindran, J., H.B. Nair, B. Sung, S. Prasad, R.R. Tekmal and B.B. Aggarwal. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem. Pharmacol. 79(11): 1640-1647, 2010.
55. Reindl, W., J. Yuan, A. Krämer, K. Strebhardt and T. Berg. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem. Biol. 15(5): 459-466, 2008.
56. Roepke, M., K. Bajbouj, D. Walluscheck, P. Schonfeld, A. Roessner, R. Schneider-Stock and H. Gali-Muhtasib. Lack of p53 augments thymoquinone-induced apoptosis and capsase activation in human osteosarcoma cells. Cancer Biol. Ther. 6(2): 160-169, 2007.
57. Rooney, S. and M.F. Ryan. Effect of alpha-hedrin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res. 25(3B): 2199-2204, 2005a.
58. Rooney, S. and M.F. Ryan. Mode of action of alpha-hedrin and thymoquinone, active constituents of Nigella sativa, against HEp-2 cancer cells. Anticancer Res. 25(6B): 4255-4259, 2005b.
59. Salem, M.L. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int. Immunopharmacol. 5: 1749-1770, 2005.
60. Salim, E.I. and S. Fukushima. Chemopreventive potencial of volatile oil from black cumin (Nigella sativa L.) seed against rat colon carcinogenesis. Nutr. Cancer 45(2): 195-202, 2003.
61. Salomi, M.J., S.C. Nair and K.R. Panikkar. Inhibitory effect of Nigella sativa and saffron (Crocus sativus) on chemical carcinogenesis in mice. Nutr. Cancer 16(1): 67-72, 1991.
62. Salomi, N.J., S.C. Nair, K.K. Jayawardhanan, C.D. Varghese and K.R. Panikka. Antitumour principles from Nigella sativa seeds. Cancer Lett. 63(1): 41-46, 1992.
63. Samarakoon, S.R., I. Thabrew, P.B. Galhena, D. De-Silva and K.H. Tennekoon. A comparison of the cytotoxic potential of standardized aqueous and ethanolic extracts of a polyherbal mixture comprised of Nigella sativa (seeds), Hemidesmus indicus (roots) and Smilax glabra (rhizome). Pharmacognosy Res. 2: 335-342, 2010.
64. Sethi, G., K.S. Ahn and B.B. Aggarwal. Targeting nuclear factor-{kappa}-B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol. Cancer Res. 6: 1059-1070, 2008.
65. Shafi, G., A. Munshi, T.N. Hasan, A.A. Alshatwi, A. Jyothy and D.K. Lei. Induction of apoptosis in HeLa cells by chloroform fraction of seed extracts of Nigella sativa. Cancer Cell Int. 9: 29, 2009.
66. Swamy, S.M. and B.K. Tan. Cytotoxic and immunopotenciating effects of ethanolic extract of Nigella sativa L. seed. J. Ethnopharmacol. 70(1): 1-7, 2000.
67. Swamy, S.M. and B.T. Huat. Intracellular glutathione depletion and reactive oxygen species generation are important in alpha-hederin-induced apoptosis of P338 cells. Mol. Cell Biochem. 245: 127-139, 2003.
68. Thabrew, M.I., R.R. Mitry, M.A. Morsy and R.D. Hughes. Cytotoxic effect of decoctoion of Nigella sativa, Hemidesmus indicus and Smilax glabra on human hepatoma HepG2 cells. Life Sci. 77(12): 1319-1330, 2005.
69. Torres, M.P., M.P. Ponnusamy, S. Chakraborty, L.M. Smith, S. Das, H.A. Arafat and S.K. Batra. Effects of thymoquinone in the expression of mucin-4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol. Cancer Ther. 9(5): 1419-1431, 2010.
70. Worthen, D.R., O.A. Ghosheh and P.A. Crooks. The in vitro anti-tumor activity of some crude and purified components of black seed, Nigella sativa L. Anticancer Res. 18(3A): 1527-1532, 1998.
71. Yi, T, S.G. Cho, Z. Yi, X. Pang, M. Rodriguez, Y. Wang, G. Sethi, B.B. Aggarwal and M. Liu. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther. 7(7): 1789-1796, 2008.